What is TrueBinding?
Founded in 2016, TrueBinding Inc. is a clinical-stage biotherapeutic company dedicated to developing novel molecules for a range of challenging diseases. Leveraging its proprietary Truebinding platform, the company has identified over six new drug targets and is advancing potentially transformative monoclonal antibody therapies for neurodegenerative conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS), as well as for stroke, oncology, and metabolic disorders. The company's focus on areas with significant unmet medical need positions it as a key player in the biopharmaceutical innovation landscape.
How much funding has TrueBinding raised?
TrueBinding has raised a total of $101M across 2 funding rounds:
Debt
$1M
Other Financing Round
$100M
Debt (2020): $1M with participation from PPP
Other Financing Round (2022): $100M, investors not publicly disclosed
What's next for TrueBinding?
The substantial enterprise-level funding and recent strategic investment signal a pivotal moment for TrueBinding. This capital infusion is expected to accelerate the company's clinical development pipeline, enabling further research and trials for its promising drug candidates. The strategic nature of the latest financing suggests potential collaborations or partnerships that could enhance market access and therapeutic impact. TrueBinding is poised to advance its mission of creating game-changing treatments for complex diseases, driven by its innovative platform and robust financial backing.
See full TrueBinding company page
